Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|February 22, 2017
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursRichard H Wilson, Tr Jeffry Evans, Mark R Middleton, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unitKhurum Khan, Joo Ern Ang, Naureen Starling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attritionAndre T Brunetto, Joo Ern Ang, David Olmos, et al.
Future Oncology (London, England)|April 14, 2021
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumorsMartina Puglisi, L Rhoda Molife, Maja Ja de Jonge, et al.
British Journal of Cancer|January 26, 2019
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumoursT R Jeffry Evans, Emma Dean, L Rhoda Molife, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2013
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumorsL Rhoda Molife, Sarah M Rudman, Salma Alam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2013
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumorsAndré T Brunetto, Joo Ern Ang, Rohit Lal, et al.
Oncotarget|December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapyRaquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
Pageof 5